JEOL
25.5.2020 08:02:15 CEST | Business Wire | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/
Development Background
Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation.
To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical control system "Neo Engine", as well as a seamless GUI "SEM Center" for full integration of a JEOL energy dispersive X-ray spectrometer (EDS). Furthermore, the JSM-IT800 offers two versions with two types of objective lens: the Hybrid Lens (HL) for general-purpose SEM and the Super Hybrid Lens (SHL) for enhanced resolution observation and various analyses.
Moreover, the SHL version comes with a new Upper Hybrid Detector (UHD) realizing higher signal-to-noise ratio images.
A new Scintillator Backscattered Electron Detector (SBED) and a Versatile Backscattered Electron Detector (VBED) are also available with the JSM-IT800.
Features
1. In-lens Schottky Plus field emission electron gun
Enhanced integration of the electron gun and low-aberration condenser lens provides higher brightness. Ample probe current is available at low accelerating voltage (100 nA at 5 kV). The unique In-lens Schottky Plus system enables various applications from high resolution imaging to fast elemental mapping, electron backscatter diffraction (EBSD) analysis, and soft X-ray emission spectroscopy (SXES), without the requirement to change lens conditions.
2. Neo Engine (New Electron Optical Engine)
Neo Engine is a cutting-edge electron optical system that accumulates JEOL core technologies of many years. Users can perform stable observation even when changing observation or analytical conditions. High operability for automatic functions is further enhanced.
3. SEM Center / EDS Integration
A GUI "SEM Center" is fully integrated as well as JEOL EDS for seamless and intuitive operations. The JSM-IT800 can be enhanced by incorporating optional software add-ons, such as SMILENAVI to assist novice users and the LIVE-AI filter (Live Image Visual Enhancer – AI) for a higher quality of live images.
4. Hybrid Lens (HL) version and Super Hybrid Lens (SHL) version
Based on a combination of the electrostatic and electromagnetic-field lens, two types of objective lens versions are available to satisfy various needs of users, achieving high spatial resolution imaging and analysis of a broad range of samples, from magnetic materials to insulators, with the features of the JSM-IT800.
5. Upper Hybrid Detector (UHD)
The UHD, built into the objective lens for the SHL version, greatly improves detection efficiency, leading to acquisition of images with a higher signal-to-noise ratio.
6. New Backscattered Electron Detectors
The Scintillator Backscattered Electron Detector (SBED, optional) has high responsiveness and is suitable to acquire material-contrast images at low accelerating voltage. The Versatile Backscattered Electron Detector (VBED, optional) with a segmented detector element design, allows the user for the choice to configure the individual segments or use preprogrammed detector settings to acquire images with three-dimensional, topographical, or compositional information.
Sales target
1) JSM-IT800 SHL version: 90 units/year
2) JSM-IT800 HL version: 50 units/year
JEOL Ltd.
3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan
Izumi Oi, President & COO
(Stock code: 6951, Tokyo Stock Exchange First Section)
www.jeol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200524005002/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom